Industrial base for bio-industry

In recent years, the Development and Reform Commission (DRC) has taken a series of initiatives to vigorously promote the clustered development of the bio-industry. At present, 22 national bio-industry bases have been approved.

In order to promote the clustered development of bio-industry, guide the social resources to focus on key areas, promote the healthy and rapid development of China's bio-industry, promote the formation of bio-industry with characteristics of the localities, and avoid duplication of construction and dispersal of resources. According to the principle of "integrated planning, giving full play to advantages, classified guidance and steady advancement", during the period of "11th Five-Year Plan", the NDRC selects areas with good industrial foundation, strong innovation ability, high marketization level and openness to build national bio-industry bases and national high-tech industry bases in batches. National high-tech industrial base. Up to now, 12 national bio-industry bases have been recognized, including Shijiazhuang, Shenzhen, Changsha, Beijing, Shanghai, Guangzhou, Wuhan, Kunming, Qingdao, Chengdu and Chongqing, as well as 10 national high-technology industrial bases in the field of bio-industry in Xi'an, Tianjin, Taizhou, Tonghua, Dezhou, Zhengzhou, Nanning, Harbin, Hangzhou and Nanchang.

Under the guidance of the state and the promotion of the local authorities, the development of bio-industry agglomeration has been greatly guided and promoted, and the spatial layout of three comprehensive bio-industry bases in Yangtze River Delta, Pearl River Delta and Beijing-Tianjin-Hebei region, as well as a number of specialized bio-industry bases in Northeast China and Central and West China has been gradually fostered in the whole country to promote the concentration of bio-industry enterprises, capital, technology, talents and other factors in the advantageous areas and accelerate the development of bio-industry to the agglomeration area. To promote the concentration of bio-enterprises, capital, technology, talents and other factors to the advantageous areas, accelerate the development of bio-industry to agglomeration and specialization, and the initial agglomeration effect. 2007, the 12 national bio-industry bases*** achieved a total industrial output value of 314.5 billion yuan, an increase of 21% year-on-year, accounting for nearly half of the country's bio-industry. In order to promote the development of bio-industry agglomeration, the localities have introduced a series of supporting preferential policies through sound institutions and mobilization of resources, laying a good foundation for the vigorous development of a number of bio-industry bases. The construction of the bases has played a significant role in creating an environment for the development of bio-industry, gathering domestic and foreign bio-industry resources on a large scale, optimizing the structure and layout of the bio-industry, forming a bio-industry growth pole with international competitiveness as soon as possible, and radiating and driving the rapid development of China's bio-industry.

The first national bio-industry base (June 2005)

Shijiazhuang base

Featured base relying on the Shijiazhuang Economic and Technological Development Zone, the core area of 17 square kilometers of the planning area, with more than 40 Huayu Pharmaceuticals, Shiyu Pharmaceuticals, four drug shares and other related biological enterprises, with a total investment of more than 10 billion yuan. At present, the key construction projects *** 178, divided into four categories: First, the chemical pharmaceutical field; Second, the field of biopharmaceuticals; Third, the field of modern traditional Chinese medicine; Fourth, the field of supporting the public ****. 2006, the realization of sales revenue of 28 billion yuan.

Construction Goals By 2012, the annual output value of the bio-industry will reach 48.5 billion yuan.

Changchun Base

Features The base will consist of 3 modules: the core area of the pharmaceutical industry is located in Changchun High-tech Industrial Development Zone, the core area of the bio-industry is laid out in Changchun Economic and Technological Development Zone, and the core area of the bio-agriculture is laid out in Jingyuetan Tourism and Economic Development Zone in the east of the city. The area is 13.4 square kilometers.

Currently, it is the largest vaccine and gene drug production base in Asia. In the field of bio-manufacturing, Changchun Dacheng Industrial Group is the world's largest lysine producer. In the field of bio-energy, the ethanol gasoline project is the only pilot city in the country; Dacheng Group invested 10 billion yuan to produce 1 million tons of chemical alcohol per year, which is one of the largest chemical alcohol projects in the country.

Construction goals By 2010, the annual output value of the bio-industry will reach 70 billion to 100 billion yuan.

Shenzhen Base

Features The core area is the Shenzhen Hi-Tech Industrial Park, and the expansion area is the Guangming and Nan'ao districts. The industrial land is nearly 3 square kilometers. the number of enterprises with sales revenue of more than 10 million yuan in 2006 is 123, among which the number of enterprises with output value of 100 million to 1 billion yuan is 36.

Through the establishment of a complete technical support platform and industrial supporting system for the bio-industry, Shenzhen will become the most marketable and functional base for the transformation of achievements, the most competitive base for the research and development and industrialization of innovative drugs, and the most technologically advanced base for the production of medical device products in China.

Construction Objectives By 2010, the annual output value of the bio-industry will reach 70 billion to 100 billion yuan.

The second batch of national bio-industry bases (October 2006)

Changsha base

Featured as the first national bio-industry base in the central region of China, the base has set up "one park and five districts". The base has formed 11 pharmaceutical industry clusters, among which, Chinese medicine detoxification drugs ranked first in China, biological vaccines and antibiotic preparations ranked first in the central and southern regions, weight-loss health care products ranked third in China, and standardized extracts of traditional Chinese medicines ranked second in China. 2007, the base achieved a total industrial output value of 7.063 billion yuan.

Construction goal By 2015, the annual output value of the bio-industry will reach 80 billion yuan.

Guangzhou base

Specialty base planning consists of two core areas, expansion area and radiation area, the overall planning area of about 13 square kilometers. It focuses on the development of four major biomedical fields, such as genetic engineering drugs, modern Chinese medicine, chemically synthesized innovative drugs, marine drugs, etc. It also focuses on the development of bio-agriculture and promotes the development of bio-service industry (biotechnology R&D, etc.). There are now more than 300 bio-enterprises of various types, of which more than 70 are on a large scale and 19 have an annual output value of more than 100 million yuan. The scale and efficiency of Guangzhou Pharmaceutical Group ranks the forefront of the national pharmaceutical industry. 2007, the total output value of Guangzhou's bio-industry was about 35.8 billion yuan, accounting for 12.5% of the city's high-tech product output value.

Construction goal By 2010, the annual output value of the bio-industry will reach 100 billion yuan.

Shanghai Base

Features a spatial layout according to the structure of "1+4", "1" is a core area, which is Zhangjiang Hi-Tech Park; "4" is four extension areas. Four expansion areas. It focuses on the development of new products in the fields of genetic engineering drugs, modern traditional Chinese medicine, chemically synthesized innovative drugs, biomedical engineering, etc., actively promotes the implementation of major projects, promotes the integration of large-scale bio-enterprise groups and the development of small and medium-sized enterprises, and gradually forms a national comprehensive bio-industry research and development, production and export base with a perfect innovation system, distinctive industrial characteristics and reasonable layout. In 2007, the total output value of Shanghai's pharmaceutical industry was RMB 38.896 billion, with an annual growth rate of more than 17% for seven consecutive years, making it one of the major emerging industries in Shanghai.

Construction Objectives By 2010, the ownership rate of independent intellectual property rights of high-tech industries in the base will reach 30%, cultivate a number of large-scale high-tech enterprises with annual sales revenue exceeding 10 billion yuan, and develop a number of high-tech industrial brands with strong competitiveness.

Beijing Base

The featured base consists of three core areas: Zhongguancun Life Science Park, Beijing Economic and Technological Development Zone and Zhongguancun Daxing Biomedical Base. As the political center, education center, science and technology center, media center, and central enterprise headquarters center of the country, Beijing has a large amount of information resources. In addition, there is a dense concentration of talents and R&D organizations. The world's top 500 companies have set up more than 150 branches in Zhongguancun, including more than 70 R&D organizations. Large domestic enterprises have also set up R&D organizations in Beijing. The base focuses on the development of genetic engineering drugs and biomedical engineering products.

Construction Goals By 2010, the added value of Beijing's high-tech industry will account for more than 22% of the regional GDP, the city's R&D investment will exceed 6% of the regional GDP, and the city will be initially built as an innovative city; by 2020, it will enter the advanced ranks of the world's innovative cities.

The Third Batch of National Bio-industry Bases (June 2007)

Qingdao Base

Features Industrial technologies are mainly concentrated in the fields of biomedicine, agricultural biotechnology and industrial biotechnology as well as traditional biotechnology. in 2007, the base realized a total industrial output value of 8.64 billion yuan, a year-on-year increase of 32.7 percent.

Construction Targets By 2010, the number of marine bio-enterprises will reach about 300, and the annual output value of bio-industry will realize 22 billion yuan; by 2015, the number of marine bio-enterprises will reach about 500, and the annual output value of bio-industry will realize 60 billion yuan; and by 2020, the annual output value of bio-industry will reach 120 billion yuan.

Wuhan Base

Features The core area includes four special industrial parks, namely Guannan Biopharmaceutical Park in East Lake Development Zone, Jiangxia Modern Traditional Chinese Medicine Park, Gedian Chemical Synthesis Innovative Drugs Park, and Nanhu Bio-agricultural Park, covering an area of 30 square kilometers.The output value of the bio-industry was 8,112 million yuan in 2007, which is an increase of 6.3% compared with the same period of last year.

It has obvious advantages in biological agents, diagnostic reagents and microchip products, diagnostic and treatment centers, etc., and biological vaccines rank fifth in China.

Construction goals By 2012, the annual output value of the bio-industry will reach 30 billion to 35 billion yuan; by 2015, it will strive to build Wuhan into the largest national bio-industry base in central China.

Chengdu Base

Features The core area is Chengdu Hi-tech Zone, where the total output value of biomedicine and bio-agriculture was 42.1 billion yuan in 2007, of which 19.3 billion yuan was for biomedicine and 22.8 billion yuan for bio-agriculture.

One is to vigorously develop biomedicine, including modern traditional Chinese medicine, innovative drugs, biomedical engineering, and biomedical services; and the other is to accelerate the development of resource technology-led bio-agriculture and bio-energy.

Construction Goals By 2010, the annual output value of the bio-industry will reach 50 billion yuan; by 2020, the annual output value of the bio-industry will reach 120 billion yuan.

Kunming Base

Features The base focuses on the development of bio-agriculture industry, which is mainly based on the seed industry, transnational major animal diseases, safety evaluation of the invasion of harmful biological species, and detection products; bio-pesticides and bio-fertilizers.

Construction Goals By 2010, the annual output value of the bio-industry will reach 50 billion yuan; by 2020, the annual output value of the bio-industry will reach 120 billion yuan.

Chongqing Base

Features Focus on the development of six major industrial fields: biomedical engineering, standardized cultivation of Chinese herbal medicines and modern pharmaceuticals, veterinary medicines and green agricultural bioproducts, characteristic bio-breeding, biomass engineering, and biotechnology service industry.

Construction Goals By 2012, the annual output value of the bio-industry will reach 100 billion yuan; by 2020, the annual output value of the industry will reach 200 billion yuan.

The fourth batch of national bio-industry bases (February 2008)

Harbin base

Specialized biomedical industry is one of the five pillar industries cultivated by Harbin City. In addition has the advantage of resources. Harbin is the national key grain and bean production areas and important green food base, Harbin jurisdiction and the surrounding areas are rich in biological resources, the development of agricultural products, especially green food and livestock products in the depth of the development of huge potential.

Construction goals By 2010, the annual output value of the bio-industry will reach 40 billion yuan, the core area of the bio-industry base accounted for more than 75% of the total output value.

Texas Base

Features The city has gathered more than 300 bio-enterprises of various types, including 102 bio-enterprises above the scale, and there are 8 existing ones with sales revenue of more than 1 billion yuan, and 38 with more than 100 million yuan.

In 2007, the bio-industry realized an output value of 22 billion yuan, of which the bio-manufacturing industry reached 16 billion yuan, accounting for 73% of all bio-industry output value. The production capacity of oligosaccharides is the first in the world, the production capacity of xylitol is the second in the world, the production capacity of oligosaccharides is the first in Asia, and the comprehensive production capacity reaches 500,000 tons, accounting for 70% of the national production capacity. It has now formed the largest production base of soybean high protein in China.

Construction goals By 2010, the annual output value of the bio-industry will reach 50 billion yuan; by 2020, the city's bio-industry added value exceeded 120 billion yuan.

Taizhou base

Featured by the initial formation of biomedicine as the core, bio-energy, bio-pesticides and other auxiliary development of the industrial system. 2007, the bio-industry sales amounted to 25.6 billion yuan, of which 18 billion yuan of biomedicine industry sales, accounting for 70.3%. The city's biomedical industry's economic total for five consecutive years, and economic benefits for nine consecutive years ranked first in Jiangsu Province. Leading companies, including Yangzijiang, Suzhong, Jichuan and Jiangshan, have been among the top 100 in the national pharmaceutical industry.

Construction goals By 2010, the annual output value of the base's biomedical industry was 55 billion yuan; by 2015, the average annual growth rate of production and sales of the biomedical industry was 20%.

Zhengzhou Base

Features Zhengzhou has outstanding bio-agricultural characteristics. The level of R&D, industrial scale, and product market share are all in the leading position in China, and have made important contributions to guaranteeing national food security. 2007 sales revenue of the bio-industry exceeded 20 billion yuan, with an average annual growth rate of 41.1%.

Construction Objectives By 2010, the annual output value of the bio-industry will reach 45 billion yuan, and the added value will reach more than 13 billion yuan; by 2015, the annual output value of the bio-industry will reach 150 billion yuan.

Tonghua Base

Features Construction of nine industrial parks and two logistics centers in three functional zones, namely, core zone, expansion zone and radiation zone In 2007, the output value of Tonghua's pharmaceutical industry was 20.2 billion yuan, accounting for 27.2% of the city's GDP and 37.4% of the pharmaceutical industry in Jilin Province.

Construction goals. By 2010, the modern Chinese medicine industry will realize an added value of 18.5 billion yuan; by 2015, the modern Chinese medicine industry will realize an added value of 37.5 billion yuan.

Nanning Base

Features Focus on the development of non-food bioenergy industry. According to the existing industrial distribution in Nanning and considering the development potential and direction of bio-industry, the development direction of Nanning high-tech industry cluster is initially drawn up, i.e., setting up four specialized bio-industry sub-bases, such as bio-energy industry sub-base, bio-medicine industry sub-base, bio-manufacturing industry sub-base, bio-agriculture industry sub-base, and so on.

Construction Objectives By 2010, the annual output value of the bio-industry will reach 69 billion yuan, of which the annual output value of bio-energy will account for 25 billion yuan of the annual output value of the bio-industry; by 2020, the annual output value of the bio-industry will reach about 153 billion yuan, of which the annual output value of bio-energy will account for more than 38% of the annual output value of the bio-industry, reaching 58 billion yuan.

Xi'an Base

Features Xi'an Hi-Tech Industrial Development Zone focuses on bio-pharmaceutical development, and Yangling focuses on bio-agricultural development.

Construction Targets By 2010, the annual output value of the bio-industry will reach 60 billion yuan, with an added value of 20 billion yuan, accounting for 3% of the province's GOP.

Tianjin Base

Features Strive to build a bio-industry pattern with export-oriented, modern biomedicine as the main body and rapid development of bio-industry and bio-agriculture, and build a first-class, world-important modern bio-industry manufacturing base and a R&D and transformation base of key technologies integrating research and development, production, sales and service. 2006 the city's bio-industry output value was nearly In 2006, the output value of the city's bio-industry was nearly 30 billion yuan.

Construction goals In 2010, the annual output value of the bio-industry will reach 60 billion yuan.

Nanchang Base

Features In 2007, the city's bio-industry assets totaled 45 billion yuan, the main business income of 42 billion yuan, completed the industrial added value of 14 billion yuan, 7.8 billion yuan in profits and taxes, and more than 80 bio-technology enterprises.

The city's bio-industry in 2007, the export value of 410 million U.S. dollars.

Construction goal By 2010, the annual output value of the bio-industry will reach 73 billion yuan.

Hangzhou Base

Features At present, it has formed a base with biotechnology drugs as the core and modern traditional Chinese medicine as the foundation. The modernized medicine and new medical devices are developing synergistically, bio-agriculture has formed characteristic advantages, and some fields are at the leading level in China. Bio-industry has been the key development of high-tech industries in Hangzhou, with medicine and agriculture as the mainstay, and the total output value of bio-industry in 2007 was about 30 billion yuan.

Construction goals By 2010, the annual output value of the bio-industry will reach 75 billion yuan; by 2015, Hangzhou will be built into a first-class, internationally oriented bio-industry base in East China and even the whole country.